Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study

BACKGROUND: Pre-clinical and clinical evidences support that simultaneous blockade of programmed death-1 (PD-1) and vascular endothelial growth factor receptor (VEGFR) can enhance antigen-specific T-cell migration, and show tolerable toxicity with favorable antitumor activity in patients. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Peiliang, Fang, Xiaozhuang, Yin, Tianwen, Tian, Hairong, Yu, Jinming, Teng, Feifei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005709/
https://www.ncbi.nlm.nih.gov/pubmed/33791214
http://dx.doi.org/10.3389/fonc.2021.628124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005709/
https://www.ncbi.nlm.nih.gov/pubmed/33791214
http://dx.doi.org/10.3389/fonc.2021.628124

Ejemplares similares